Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of iparomlimab/tuvonralimab + epirubicin + anlotinib as first-line treatment for unresectable recurrent or metastatic dedifferentiated liposarcoma
ChiCTR2600134813Phase 2Not yet recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Nov 2026
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of iparomlimab + tuvonralimab, epirubicin and anlotinib in dedifferentiated liposarcoma (DDL) and Liposarcoma (3 arms), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Objective Response Rate. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
iparomlimab + tuvonralimabepirubicinanlotinib
03
Conditions
dedifferentiated liposarcoma (DDL)Liposarcoma
Beyond the preview
Go deeper on ChiCTR2600134813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600134813.